• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

ATS: COPD Drugs Slow Disease Progression, Study Confirms

Article

SAN FRANCISCO -- Inhaled corticosteroid and long-acting beta2 agonist therapy significantly slows the progressive lung function decline of chronic obstructive pulmonary disease (COPD).

SAN FRANCISCO, May 22 -- Inhaled corticosteroid and long-acting beta2 agonist therapy significantly slows the progressive lung function decline of chronic obstructive pulmonary disease (COPD).

Fluticasone proprionate plus salmeterol (Advair) reduced the decline in forced expiratory volume (FEV1) by 16 mL per year compared with placebo (P

Related Content
FDA Approves Ensifentrine for Maintenance Treatment of COPD in Adults: Daily Dose / image credit: ©New Africa/AdobeStock

FDA Approves Ensifentrine for Maintenance Treatment of COPD in Adults: Daily Dose

Sydney Jennings
July 8th 2024
Article

Your daily dose of the clinical news you may have missed.

FDA Decision on Dupilumab for COPD Pushed Back to September 2024

FDA Decision on Dupilumab for COPD Pushed Back to September 2024

Grace Halsey
May 31st 2024
Article

FDA has no concerns about the "approvability" of dupilumab for the new indication but needs additional time to review phase 3 data it requested early in May.

Tezepelumab Found to Reduce Rate of COPD Exacerbations in Persons with Wide Range of Blood Eosinophil Levels: Daily Dose / image credit: ©New Africa/AdobeStock

Tezepelumab Found to Reduce Rate of COPD Exacerbations in Persons with Wide Range of Blood Eosinophil Levels: Daily Dose

Sydney Jennings
May 28th 2024
Article

Your daily dose of the clinical news you may have missed.

Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes ©Crystal Light/stock.adobe.com

Find and Treat Asthma and COPD: All Interventions Make a Difference, Study Concludes

Grace Halsey
May 22nd 2024
Article

Adults with undiagnosed asthma or COPD who were randomly detected and assigned to specialist or usual care all had improved outcomes at 1 year, Canadian authors reported.

Dupilumab reduced annualized rate of exacerbations in COPD in NOTUS Surya P Bhatt, MD, MSPH Courtesy University of Alabama

Dupilumab in Replicate Phase 3 Trial Significantly Reduces COPD Exacerbations, Improves Lung Function, with PDUFA Date in Sight

Grace Halsey
May 21st 2024
Article

Dupilumab reduced COPD exacerbations by 34% in adults with uncontrolled symptoms and evidence of T2 inflammation, and significantly improved lung function.

Tezepelumab Reduces COPD Exacerbations, Improves Lung Function in Phase 2a COURSE Trial ©MichaelVi/stock.adobe.com

Tezepelumab Reduces Rate of COPD Exacerbations in Individuals with Wide Range of Blood Eosinophil Levels: Phase 2a COURSE Trial Findings

Grace Halsey
May 20th 2024
Article

ATS: The biologic shows promise in a range of people with COPD, particularly those with BEC levels of 150 cells/μL and greater, according to findings released at the 2024 ATS meeting.

© 2024 MJH Life Sciences

All rights reserved.